AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
201.31
-7.86 (-3.76%)
Mar 25, 2025, 4:00 PM EST - Market closed
AbbVie Revenue
In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth. AbbVie had revenue of $15.10B in the quarter ending December 31, 2024, with 5.60% growth.
Revenue (ttm)
$56.33B
Revenue Growth
+3.71%
P/S Ratio
6.57
Revenue / Employee
$1,024,255
Employees
55,000
Market Cap
356.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
ABBV News
- 4 days ago - 2025 Dividend Kings: Strong Run Continues - Seeking Alpha
- 5 days ago - My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys - Seeking Alpha
- 7 days ago - Widely used drugs on US imports list from Europe - Reuters
- 10 days ago - ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients - PRNewsWire
- 11 days ago - Drugmakers agree to participate in second round of price negotiations - Reuters
- 12 days ago - AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk - Seeking Alpha
- 14 days ago - Stocks beating the stock market's recent Trump slump have this in common - Market Watch
- 14 days ago - AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript) - Seeking Alpha